New cancer drug tested on patients out of options
NCT ID NCT04261413
Summary
This early-stage study tested a new cancer drug called RS-0139 to find a safe dose and see how the body processes it. It involved 16 adults with advanced solid tumors that had returned or spread and who had no other standard treatments left. The main goal was to check for serious side effects while also looking for early signs that the drug might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi
Ankara, Turkey (Türkiye)
-
Koç University Hospital Phase I Center
Istanbul, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.